DLA Piper advises Brookline Capital Acquisition Corp. in the closing of its business combination with Apexigen, Inc.

DLA Piper suggested Brookline Capital Acquisition Corp., a specific intent acquisition business, in the closing of its enterprise mixture with Apexigen, Inc., a scientific-stage biopharmaceutical firm. The merged, publicly traded enterprise will function below the name Apexigen, and its widespread stock commenced buying and selling on the Nasdaq Money Current market on August 1, 2022 beneath the ticker image “APGN.”

Apexigen is a medical-stage biopharmaceutical organization focusing on the discovery and advancement of innovative antibody-dependent therapeutics for the therapy of most cancers with a emphasis on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is currently in Section 2 scientific progress, and also involves many preclinical stage immuno-oncology programs.

“On behalf of our deal team, it was an honor doing the job with Brookline Capital Acquisition and combining our SPAC M&A capabilities with our working experience in the healthcare sector to assist this transaction and Apexigen’s long term progress,” said Jeffrey Selman, chair of DLA Piper’s SPAC Transactional apply and the associate who led the firm’s deal group.

“We are pretty happy to have labored with the exceptional staff at DLA Piper, led by Jeff Selman and James Kelly. Their guidance and emphasis was instrumental in the timely completion of this complicated transaction, and for that we are grateful,” reported Samuel Wertheimer, Chairman and CEO of Brookline Money Acquisition Corp.

“Congratulations to Brookline Money Acquisition and Apexigen on this offer. This is a major milestone for Apexigen as it carries on to unlock progressive solutions in the oncology space, and we’re grateful to be a element of it,” said James Kelly, head of DLA Piper’s New York Non-public Fairness apply.

In addition to Selman (San Francisco) and Kelly (New York), the DLA Piper workforce representing Brookline Funds Acquisition included partners Peter Ekberg (Minneapolis), Alan Seem, Carole Bellis (equally in Silicon Valley) and Ilya Bubel (New York), and associates Spencer Hodson (Sacramento), Wei Li (Silicon Valley) and Peter Phillips (New York).

With a lot more than 1,000 corporate attorneys globally, DLA Piper will help purchasers execute sophisticated transactions seamlessly although supporting shoppers throughout all phases of improvement. The firm has been rated range just one in world-wide M&A volume for 12 consecutive decades, according to Mergermarket.

The firm’s Health care sector is composed of a multidisciplinary authorized group with niche knowledge in health-related organization and lawful troubles. The staff routinely functions with companies and economic institutions, personal buyers, personal fairness teams, venture cash money, institutional buyers and portfolio organizations in all kinds of health care transactions.